Trevena (NASDAQ:TRVN) Stock Price Passes Below 200-Day Moving Average – Here’s Why

Trevena, Inc. (NASDAQ:TRVN)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.99 and traded as low as $1.80. Trevena shares last traded at $1.98, with a volume of 12,859 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on Trevena in a research report on Monday, October 7th. They set a “sell” rating on the stock.

Trevena Stock Performance

The business’s 50 day moving average is $4.20 and its two-hundred day moving average is $6.99. The firm has a market capitalization of $1.45 million, a PE ratio of -0.04 and a beta of 1.02.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million during the quarter. As a group, equities research analysts predict that Trevena, Inc. will post -32.25 EPS for the current year.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.